Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 277-823-9 | CAS number: 74336-59-7
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Endpoint summary
Administrative data
Link to relevant study record(s)
Description of key information
Based on the physico-chemical properties and the absence of findings in toxicity studies, the substance is considered to be non bioavailable.
Key value for chemical safety assessment
- Bioaccumulation potential:
- no bioaccumulation potential
Additional information
Assessment of the Toxicokinetic Behaviour of
3-[(4-chloro-2-nitrophenyl)azo]-2-methylpyrazolo[5,1-b]quinazolin-9(1H)-one (CAS-No.74336-59-7)
There were no studies available in which the toxicokinetic properties of the substance were investigated.
The substance (molecular weight of 382.77 g/mol) is an odourless, orange powder at room temperature with an extremely low water solubility (measured water solubility: < 10 µg/L at 20°C and pH 6.1-6.3 (BASF 2011, see chapter "water solubility"). The substance is not prone to hydrolysis. Additionally, due to the structure of the molecule and the extremely low water solubility of the substance biodegradation is not expected. The log Po/w is 2 at 23°C and pH = 6.2 (BASF 2011, see chapter "partition coefficient"), indicating that accumulation of the substance is not expected.
ABSORPTION
No indication of a substance specific systemic toxicity can be found in an acute toxicity study in rats with oral administration by gavage (see chapter „acute toxicity“) as well as in a subacute toxicity study and reproductive toxicity screening study in rats with oral application (see chapter „repeated dose toxicity“ and "reproductive toxcity"). Therefore absorption and bioavailability of the test substance after oral administration is not expected (BASF 1981, see chapter "acute oral toxicity" and chapter "repeated dose toxicity").
There are no data available about dermal and inhalative absorption. Nevertheless, due to the low water solubility dermal uptake is likely to be very low. Based on the log Po/wof 2, penetration into the stratum corneum may occur, but due to the limited transfer rate into the epidermis, systemic absorption is expected to be low (ECHA guidance document 7c, 2008).
The test substance is a non-volatile powder at room temperature (vapour pressure of less than 1 x 10e-6 hPa at 20 °C, BASF 2011, see chapter "vapour pressure"), with only a very small proportion of particles of inhalative and respirable particle size (< 100 µm: 7.4% and < 10 µm: 0.3% BASF 2011, see chapter "particle size distribution"), thus significant inhalation exposure is not anticipated.
Based on the physico-chemical properties and the absence of systemic toxicity in acute and repeated-dose studies, absorption of the test substance is unlikely.
DISTRIBUTION
There is no experimental evidence of distribution.
METABOLISM
There is no experimental evidence of metabolism. In theory the chemical structure indicates that the most likely route of biotransformation is by reductive cleavage of the azo bond either by bacterial enzymes in the gut or by microsomal azo reductase in the liver. However, azo reduction products typically cause adverse effects on liver and blood and such (or any) effects were not observed for this substance. So metabolism is not expected due to lack of absorption after oral administration of the test substance. Studies on genetic toxicity (bacterial reverse mutation assay (Ames-Test), in vitro mammalian cell gene mutation and chromosome aberration test) see chapter "genetic toxicity") were negative and gave no indications of a reactivity of the test substance or its metabolites under the test conditions (i.e. no increased mutagenicity or cytotoxicity in treatments with and without metabolic activation).
EXCRETION
The observation of orange faeces in the acute and repeated oral study is assessed as indication of intestinal passage of the pigment. The extremely low water solubility of the test substance makes absorption from the gastro-intestinal tract unlikely and the substance is expected to be eliminated unchanged (ECHA guidance document 7c, 2008).
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
